Loading…
Reported covered position: Legislative Correspondent, Legislative Assistant, and Sr. Legislative Assistant for Rep. John Sullivan (OK Dist. 1); Legislative Director and then Chief of Staff for Rep. Bill Flores (TX Dist. 17).
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2026 · third_quarter · Q3
Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues pertaining to Medicare Part D; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Source: Senate LDA
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Issues related to Pharmacy Benefit Manager reform, S. 392 Give Kids a Chance Act; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; Issues related to implementation of the Inflation Reduction Act (H.R. 5376).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1300/S. 297 PSA screening bills; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Impacts and Outcomes for Health Career Training Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; Issues related to implementation of the Inflation Reduction Act (H.R. 5376).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1300/S. 297 PSA screening bills; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; Issues related to implementation of the Inflation Reduction Act (H.R. 5376).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Issues related to Pharmacy Benefit Manager reform, S. 392 Give Kids a Chance Act; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills).
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Sloan Canyon Conservation and Lateral Pipeline Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform, S. 392 Give Kids a Chance Act; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills).
Right to Try Clarification Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Right to Try Clarification Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Right to Try Clarification Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Medicaid VBPs for Patients Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Medicaid VBPs for Patients Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Medicaid VBPs for Patients Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Medicaid VBPs for Patients Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Child Tax Credit for Pregnant Moms Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub.L.96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Out Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub.L.116-283).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Issues related to OBBA (Pub. L. No: 119-21).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2026 · second_quarter · Q2
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2026 · first_quarter · Q1
Issues related to OBBA (Pub. L. No: 119-21).
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2025 · fourth_quarter · Q4
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Issues related to OBBA (Pub. L. No: 119-21).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2025 · third_quarter · Q3
Issues related to OBBA (Pub. L. No: 119-21).
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2025 · second_quarter · Q2
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2025 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1300/S. 297 PSA screening bills; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; Issues related to implementation of the Inflation Reduction Act (H.R. 5376).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2024 · fourth_quarter · Q4
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2024 · third_quarter · Q3
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2024 · second_quarter · Q2
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2024 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · fourth_quarter · Q4
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · third_quarter · Q3
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · second_quarter · Q2
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · second_quarter · RA
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · fourth_quarter · Q4
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · third_quarter · Q3
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · second_quarter · Q2
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · fourth_quarter · Q4
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · third_quarter · Q3
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · second_quarter · Q2
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub.L.96-517).
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · first_quarter · Q1
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub.L.96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Out Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub.L.116-283).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2008 · first_quarter · RA
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Issues related to OBBA (Pub. L. No: 119-21).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Issues related to Pharmacy Benefit Manager reform, S. 392 Give Kids a Chance Act; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; issues related to implementation of the Inflation Reduction Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).